What is Clinofar?
Clinofar is the chemical name for salt. Clinofar can reduce some types of bacteria in certain body secretions, such as saliva.
Clinofar inhalation is used to produce sputum (mucus, or phlegm) from the mouth to help improve lung function in people with cystic fibrosis, or to collect sputum for medical testing. This medication may also be used to dilute other medications inhaled through a nebulizer.
Clinofar inhalation may also be used for other purposes not listed in this medication guide.
An indication is a term used for the list of condition or symptom or illness for which the medicine is prescribed or used by the patient. For example, acetaminophen or paracetamol is used for fever by the patient, or the doctor prescribes it for a headache or body pains. Now fever, headache and body pains are the indications of paracetamol. A patient should be aware of the indications of medications used for common conditions because they can be taken over the counter in the pharmacy meaning without prescription by the Physician.
Airlife Modudose Clinofar as isotonic solution: the dehydration of various origins. To maintain the volume of blood plasma during and after surgery. As a solvent for various drugs.
Hypertonic solution: violations of water-electrolyte metabolism: lack of sodium and chlorine ions; hypoosmotic dehydration of various origins (due to prolonged vomiting, diarrhea, burns with a gastric fistula, pulmonary hemorrhage, intestinal bleeding).
Eye drops and ointment: irritation of the cornea with inflammatory and allergic diseases (combined therapy).
How should I use Clinofar?
Use Clinofar nebulizer solution as directed by your doctor. Check the label on the medicine for exact dosing instructions.
- Clinofar nebulizer solution is for inhalation in a nebulizer only. Do not take Clinofar nebulizer solution by mouth or inject it.
- Clinofar nebulizer solution is used to dilute other medicines. Follow the instructions provided by your doctor.
- Clinofar nebulizer solution may come in a single-dose vial or in a container with multiple doses. Be sure to use the proper amount of Clinofar nebulizer solution. If you are using Clinofar nebulizer solution from a multiple-dose container, use a measuring device marked for medicine dosing. Ask your pharmacist for help if you are unsure of how to measure your dose.
- If you are using a vial, use your dose immediately after opening the vial and throw away any unused medicine. Do not save the contents of an opened vial for later use.
- Do not use Clinofar nebulizer solution if it contains particles, is cloudy or discolored, or if the vial is cracked or damaged.
- This product is intended to dilute other medicines for use in a nebulizer. If you miss a dose of your medicine, follow the missed dose instructions for the medicine that you are mixing with this product.
Ask your health care provider any questions you may have about how to use Clinofar nebulizer solution.
Uses of Clinofar in details
There are specific as well as general uses of a drug or medicine. A medicine can be used to prevent a disease, treat a disease over a period or cure a disease. It can also be used to treat the particular symptom of the disease. The drug use depends on the form the patient takes it. It may be more useful in injection form or sometimes in tablet form. The drug can be used for a single troubling symptom or a life-threatening condition. While some medications can be stopped after few days, some drugs need to be continued for prolonged period to get the benefit from it.
Clinofar is used as a source of electrolytes (minerals in body fluids) and water to prevent dehydration (when loss of water exceeds water intake) and replenish the loss of sodium from body fluids in conditions like metabolic alkalosis (acid-base imbalance in body fluids that can cause serious complications) or diarrhea. It is also used as a solvent for reconstitution of medications or diluting agent for administration of medications intravenously.
Clinofar, also known as salt, common salt, table salt or halite, is an ionic compound with the chemical formula NaCl, representing a 1:1 ratio of sodium and chloride ions. Clinofar is the salt most responsible for the salinity of seawater and of the extracellular fluid of many multicellular organisms. It is listed on the World Health Organization Model List of Essential Medicines.
All injections in VIAFLEX plastic containers are intended for intravenous administration using sterile and nonpyrogenic equipment.
As directed by a physician. Dosage, rate, and duration of administration are to be individualized and depend upon the indication for use, the patient’s age, weight, clinical condition, concomitant treatment, and on the patient’s clinical and laboratory response to treatment.
When other electrolytes or medicines are added to this solution, the dosage and the infusion rate will also be dictated by the dose regimen of the additions.
Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration whenever solution and container permit. Use of a final filter is recommended during administration of all parenteral solutions, where possible.
Do not administer unless the solution is clear and seal is intact.
Additives may be incompatible with Clinofar Injection, USP. As with all parenteral solutions, compatibility of the additives with the solution must be assessed before addition. Before adding a substance or medication, verify that it is soluble and/or stable in water and that the pH range of Clinofar Injection, USP is appropriate. After addition, check for unexpected color changes and/or the appearance of precipitates, insoluble complexes or crystals.
The instructions for use of the medication to be added and other relevant literature must be consulted. Additives known or determined to be incompatible must not be used. When introducing additives to Clinofar Injection, USP, aseptic technique must be used. Mix the solution thoroughly when additives have been introduced. Do not store solutions containing additives.
After opening the container, the contents should be used immediately and should not be stored for a subsequent infusion. Do not reconnect any partially used containers. Discard any unused portion.
Caution must be exercised in the administration of Clinofar Injection, USP to patients receiving corticosteroids or corticotropin
Clinofar side effects
Post-Marketing Adverse Reactions
The following adverse reactions have been identified during postapproval use of Clinofar Injection, USP. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.
The following adverse reactions have been reported in the post-marketing experience during use of 0.9% Clinofar Injection, USP and include the following:
hypersensitivity/infusion reactions, including hypotension, pyrexia, tremor, chills, urticaria, rash, and pruritus.
Also reported are infusion site reactions, such as infusion site erythema, injection site streaking, burning sensation, and infusion site urticaria.
The following adverse reactions have not been reported with 0.9% Clinofar Injection, USP but may occur: hypernatremia, hyperchloremic metabolic acidosis, and hyponatremia, which may be symptomatic.
Hyponatremia has been reported for 0.45% Clinofar Injection, USP.
The following adverse reactions have not been reported with 0.45% Clinofar Injection, USP but may occur: hyperchloremic metabolic acidosis, hypersensitivity/infusion reactions (including hypotension, pyrexia, tremor, chills, urticaria, rash, and pruritus), and infusion site reactions (such as infusion site erythema, injection site streaking, burning sensation, infusion site urticaria).
If an adverse reaction does occur, discontinue the infusion, evaluate the patient, institute appropriate therapeutic countermeasures and save the remainder of the fluid for examination if deemed necessary.
Due to potential toxicity of benzyl alcohol in newborns, Bacteriostatic Clinofar Injection, USP, 0.9% containing benzyl alcohol must not be used in this patient population.
Bacteriostatic Clinofar Injection, USP, 0.9% should not be used for fluid or Clinofar replacement.
Active ingredient matches for Clinofar:
Sodium Chloride in Greece.
- DailyMed. «AMINO ACIDS; CALCIUM ACETATE; GLYCERIN; MAGNESIUM ACETATE; PHOSPHORIC ACID; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE: DailyMed provides trustworthy information about marketed drugs in the United States. DailyMed is the official provider of FDA label information (package inserts).». https://dailymed.nlm.nih.gov/dailyme… (accessed September 17, 2018).
- PubChem. «sodium chloride». https://pubchem.ncbi.nlm.nih.gov/com… (accessed September 17, 2018).
- DrugBank. «Sodium Chloride». http://www.drugbank.ca/drugs/DB09153 (accessed September 17, 2018).
- DTP/NCI. «sodium chloride: The NCI Development Therapeutics Program (DTP) provides services and resources to the academic and private-sector research communities worldwide to facilitate the discovery and development of new cancer therapeutic agents.». https://dtp.cancer.gov/dtpstandard/s… (accessed September 17, 2018).
- Wikipedia. «sodium chloride: Inorganic chemical information in Wikipedia.». https://en.wikipedia.org/wiki/Sodium… (accessed September 17, 2018).
The results of a survey conducted on ndrugs.com for Clinofar are given in detail below. The results of the survey conducted are based on the impressions and views of the website users and consumers taking Clinofar. We implore you to kindly base your medical condition or therapeutic choices on the result or test conducted by a physician or licensed medical practitioners.
|There are no reviews yet. Be the first to write one!|
Information checked by Dr. Sachin Kumar, MD Pharmacology